Spots Global Cancer Trial Database for Trial of TG4023 Combined With Flucytosine in Liver Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of TG4023 Combined With Flucytosine in Liver Tumors
Official Title: A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.
Study ID: NCT00978107
Conditions
Interventions
Study Description
Brief Summary: This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary hepatic tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hôpitaux Civils de Colmar, Colmar, , France
Institut Paoli Calmette,, Marseille, , France
Hôpitaux Civils de Lyon,, Pierre Benite, , France
Centre René Gauducheau, Saint Herblain, , France
Hôpitaux Universitaires de Strasbourg, Strasbourg, , France
Institut Claudius Regaud, Toulouse, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
